AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 91 min read$PCRX

RIKER LAUREN sold $218K of PCRX

RIKER LAUREN (Senior Vice President, Finance) sold 6,000 shares of Pacira BioSciences, Inc. (PCRX) at $36.32 ($0.22M total) on 2026-10-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RIKER LAUREN
Published Oct 9, 2026, 11:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 11:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCRX
Bearish
medium confidence
Mentioned
$PCRX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCRXBearishLow
01

Why it matters

The disclosed sale reduces the insider's stake, which may be interpreted as a lack of confidence, but the modest size limits market reaction.

02

Market read

A small insider sale by a senior finance officer, reported via a Form 4 filing, offers limited trading relevance.

03

What to watch

Potential upcoming corporate actions or earnings that prompted the 10b5-1 plan execution.

Relevance 3/10Novelty 3/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$PCRXBearishMedium confidence
Context

Senior Vice President of Finance Riker Lauren sold 6,000 shares for $217,920 via a 10b5-1 plan, reducing his holdings to 62,284 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell

Evidence & confidence

Form 4 filings are primary disclosures; the amount is modest but the sale by a senior finance officer can influence sentiment.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine and unlikely to shift sector sentiment.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity move unrelated to company fundamentals, so the stock may remain stable.

Key entities

  • Person
    Riker Lauren

    Senior Vice President, Finance at Pacira BioSciences

  • Company
    Pacira BioSciences, Inc.

    Biopharmaceutical company (ticker PCRX)

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCRX insider trading history →

Related articles

OCT 12
$VTRSHighAI 9/10

Viatris to Acquire Pacira in US$1.65bn Pain Management Deal

Viatris (VTRS) announced plans to acquire Pacira BioSciences (PCRX) for approximately US$1.65bn. Pacira generated US$746m in revenue over the last 12 months. The deal aims to strengthen Viatris' portfolio in non-opioid pain management, adding Pacira's Exparel and Zilretta to its offerings. The acquisition is expected to be immediately accretive and is set to close by the end of 2026.

healthcare-digital.com3 min
OCT 10
$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

tradingview.com1 min
OCT 10
$VTRSHighAI 9/10

Viatris to Acquire Pacira Biosciences for USD 1.65 Billion, Adds Exparel, Zilretta to Pain Portfolio

Viatris (VTRS) will acquire Pacira Biosciences (PCRX) for $1.65B, or $36.50 per share, a 44.8% premium. Pacira shares rose 44%, Viatris fell 2%. The deal adds Exparel and Zilretta to Viatris' pain portfolio, with 2025 sales of $575.1M and $116.6M. Viatris plans to fund the deal with cash and short-term borrowings, expecting minimal leverage impact and immediate accretion.

medicaldialogues.in6 min